While its preclinical promise is undeniable, its path to becoming a widely accepted and approved therapeutic agent requires a concerted effort to generate robust human clinical data, address regulatory concerns, and precisely define its optimal applications
Semaglutide seems to have a slight edge in reducing the risk of side effects, based on studies that assessed the risk of GI upset and pancreatitis.2 10 In our conversations with diabetic GLP-1 RA users, weve found that doctors will often start patients out on Ozempic, which uses the same active ingredient as Wegovy (semaglutide), as opposed to a drug based on tirzepatide
p = 0.004), the risk of intrauterine growth retardation (IUGR) by 11% ( p = 0.013), and the risk of preterm birth by 7% (
Oral semaglutide (at $289/mo month-to-month, or from $249/mo on the 6-month plan) may cause less nausea than injections for some patients, since it avoids the rapid peak blood levels that trigger stomach upset